Detalles de la búsqueda
1.
SARS-CoV-2 Permissive Glioblastoma Cell Line for High Throughput Antiviral Screening
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-480238
2.
Intracellular flow cytometry complements RT-qPCR detection of circulating SARS-CoV-2 variants of concern
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-478775
3.
Combination of the parent analogue of Remdesivir (GS-441524) and Molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-512054
4.
The role of airborne transmission in a large single source outbreak of SARS-CoV-2 in a Belgian nursing home in 2020
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21267362
5.
Identification of TMEM106B as proviral host factor for SARS-CoV-2
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-316281
6.
Failure of the cobas(R) SARS-CoV-2 (Roche) E-gene assay is associated with a C-to-T transition at position 26340 of the SARS-CoV-2 genome
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20083337
7.
Early SARS-CoV-2 reinfections within 60 days highlight the need to consider antigenic variations together with duration of immunity in defining retesting policies
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22273172
8.
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-474275
9.
The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-474086
10.
Genetic diversity and evolution of SARS-CoV-2 in Belgium during the first wave outbreak
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-450330
11.
Carbohydrate-Binding Protein from Stinging Nettle as Fusion Inhibitor for SARS-CoV-2 Variants of Concern
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-499297
12.
Real-world monitoring of BNT162b2 vaccine-induced SARS-CoV-2 B and T cell immunity in naive healthcare workers: a prospective single center study
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22269081
13.
Full protection against all four SARS-CoV-2 variants of concern (VOC) in hamsters requires revision of spike antigen used for vaccination.
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-468374
14.
SARS-CoV-2 20I/501Y.V1 variant in the hamster model
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-440435
15.
Comparative infectivity and pathogenesis of emerging SARS-CoV-2 variants in Syrian hamsters
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-433062
16.
mRNA vaccines and hybrid immunity use different B cell germlines to neutralize Omicron BA.4 and BA.5
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-502828
17.
Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4 and BA.5 in patients receiving monoclonal antibodies
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22278699
18.
Seroneutralization of Omicron BA.1 and BA.2 in patients receiving anti-SARS-CoV-2 monoclonal antibodies.
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22272066
19.
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-516888
20.
The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-495116